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ABSTRACT
KYLE FORD GORDON: CELL PROLIFERATION AND VIABILITY
INHIBITION BY RESVERATROL ON BREAST CANCER CELL LINES
(Under the direct of Drs. Yu-Dong Zhou and Dale G. Nagle)

Antioxidants are well-known for their various health benefits. They are able to
protect cells from being damaged by free radicals that are produced by vital biochemical
processes. It has long been known that antioxidants are important in our everyday health,
but their potential as disease preventers and potential therapeutic agents is a relatively
new field of study. Resveratrol, a natural polyphenol and well-known antioxidant, is
found in plants, fruits, and products derived from them, like red wine. Resveratrol has
been shown to have various properties, including antiaging, anti-aggregation of platelets,
anti-inflammatory, and anticancer activities. Because of their many health benefits,
antioxidants have become a hot topic in cancer research. Oxidative stress, which occurs
when there is an imbalance between reactive oxygen species (ROS) and antioxidants, has
been shown to be a potential cause of cancer development. Our research group tested the
effects of resveratrol, vitamins C and E, and the green tea catechin, epigallocatechin
gallate (EGCG), on various breast cancer cell lines, though this review will focus on the
chemotherapeutic potential of resveratrol. In the experiments, breast cancer MCF-7,
MDA-MB-231, BOM 231, and MCF-7-BOM cell lines were treated with various
concentrations of resveratrol. A Sulforhodamine B viability assay was used to assess the
percent inhibition of resveratrol on each cell line. The experiments showed that
resveratrol is an inhibitor of breast cancer cells in a concentration and cell line dependent
manner.
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Introduction: Breast Cancer
Cancer has become a major health problem across the globe. It is now the second
leading cause of death in the United States. The American Cancer Society expects cancer
to kill over 600,000 people in 2019 (27). Cancer is not only widespread but it is an
extremely variable disease, as the National Cancer Institute recognizes over 100 different
types of cancer. Cancer is a ruthless disease that takes advantage of a vital life process.
The human body is made of trillions of cells. As old cells die, new ones divide and take
their place. Cancer begins to take form when a buildup of cellular mutations cause some
of these cells to become abnormal and divide uncontrollably. According to the World
Health Organization, breast cancer is the most common form of cancer in the world
(other than skin cancer), with over two million cases reported in 2018 (6). Most breast
cancer occurs in women, with the number of cases in women occurring at a rate 100times greater than in men (24). Like all cancers, breast cancer is an extremely complex
and heterogeneous disease. Despite the variability of breast cancer, great strides have
been made to identify risk factors that could lead to the development of breast cancer.
Breast cancer associated gene 1 and 2 (BRCA1 and BRCA2) are two of the most wellknown risk factors for breast cancer at the genomic level. These genes encode tumor
suppressor proteins, which help to combat tumor growth when functioning properly.
However, genetics are not solely responsible for the development of breast cancer.
Aging, hormone levels, lifestyle, and gender can also greatly influence the development
of breast cancer. Despite the high incidence of breast cancer, there have been new
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developments in recent years to combat this disease. This is because of new therapies,
early detection, and knowledge about the prevention of breast cancer.
The breasts are a very complex and important part of human anatomy. Breast
tissue undergoes many changes during the course of a lifetime. From birth to the end of
menopause they are constantly growing and their cells are dividing. After puberty, breast
tissue undergoes even greater changes during breastfeeding and menopause. These
changes are necessary to breastfeed children, but they also create an opportunity for
cancer to manifest. Cancer results from the buildup of mutations over time, which are
more common in tissues that have cells which divide often. Breast tissue contains
approximately 20 lobes which contain smaller lobules that are responsible for producing
milk. The lobules are able to move this milk to the nipple through tubes called ducts.
Breast cancer typically begins in these ducts (ductal carcinoma) or in the lobules (lobular
carcinoma) (2).
Breast cancer can form as a result of genetic pre-dispositions, environmental
factors, or a combination of both. Every person has a unique set of DNA that codes for
the human body and all of its processes. Genes are small sections of this DNA that code
for individual traits and provide variability in a population. Every person has two copies
of each gene: one from each parent. If one parent has a mutation in a certain gene, their
child has a high chance of inheriting that gene. Recent advances in DNA technology have
allowed researchers to gain a much better understanding of genetic involvement in
cancer. Oncogenes and tumor suppressor genes are thought to be two of the biggest
genetic players in the development of cancer. Oncogenes are mutated genes that have the
potential to become cancerous, while tumor suppressor genes are responsible for tumor
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repression. Just as the name suggests, a loss in function in a tumor suppressor gene can
allow for tumor growth. Most inherited cases of breast cancer involve the genes BRCA1
or BRCA2. When these genes are not functioning properly, the risk for developing breast
or ovarian cancer increases significantly. The BRCA1 and BRCA2 mutations account for
approximately 10% of all breast cancer cases (29). Approximately 50% of women with
either the BRCA1 or BRCA2 gene mutation will develop breast cancer at some point in
their life (1). Various BRCA1 mutations can lead to dysregulation of the cell cycle,
genetic instability, and eventually, apoptosis. The proteins encoded by BRCA2 regulate
chromosomal breaks and repairs. If an individual inherits a deleterious BRCA1/2 gene,
their risk for breast cancer increases dramatically. These genes are inherited in an
autosomal dominant fashion, so only one mutated allele is necessary for deleterious
effects to appear (24).
Human epidermal growth factor receptor 2 (HER2) overexpression increases the
number of cancer stem cells and is found in approximately 20% of primary breast cancers
(24). Functioning as a tyrosine kinase, HER2 protein overexpression can lead to
uncontrolled cell growth. Additionally, tumor cells that present high levels of HER2 have
a poorer prognosis (15). Epidermal growth factor receptor (EGFR), also known as HER1,
is a cell surface protein that promotes cell proliferation, invasion, angiogenesis, and
apoptosis prevention. Patients with tumors that at are EGFR-positive have a much poorer
prognosis than EGFR-negative patients (24). Furthermore, more than half of patients with
triple-negative breast cancer (TNBC), the deadliest form of breast cancer, have EGFR
overexpression. Estrogens (ERs) are sex hormones that promote the development and
maintenance of the female sex characteristics. They are one of the most prominent
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players in breast cancer because of their cell proliferating and growth stimulating
capabilities. Estrogens are essential to the development of the lobes in the female breast,
but they can promote breast cancer if they are present at high levels. In fact, in ER+
breast cancer patients, the concentration of estrogen in breast tissue has been shown to be
20-times higher than in normal breast tissue (18). Thus, a common treatment for breast
cancer patients is to block estrogen from binding to its receptor through hormone therapy.
There are two types of ERs that have different physiological roles; ERa and ERb.
Phytoestrogens, such as resveratrol, are found in plants and have been linked to a
decrease in risk for developing breast cancer. Resveratrol is able to mitigate the cell
proliferating capabilities of both subtypes of ERs but was shown to promote cell growth
in in late stage cancer cells that lack ERb (18).
Environmental risk factors for developing breast cancer range from lifestyle to
aging. Aging, as it is in all cancers, is perhaps the biggest determinant in the development
of breast cancer. Interestingly, the median age for the development of breast cancer varies
with ethnicity. For example, according to the National Cancer Society, the median age of
a breast cancer diagnosis for white women is 63, while that for African American women
is 59 (3). Therefore, it is advised that women over the age of 40 have a mammography
screening. Reproductive factors such as early menarche (first menstruation), late child
bearing, low parity (number of child births), and late menopause can all increase the risk
of developing breast cancer. Multiple successful pregnancies have been shown to
decrease the risk of developing breast cancer after the age of 40 regardless of the age at
first birth, but increases the risk for breast cancer diagnosis before 40 years of age (3).
The relationship between reproductive factors and breast cancer development is very
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complex, but a trend has emerged between certain factors and the development of
estrogen/progesterone (ER/PR) positive or negative tumors. Both natural estrogen
production and exogenous estrogen consumption are associated with breast cancer risk.
Estrogen plays an important role in premenopausal women, but an ovariectomy can be
performed to reduce the risk of breast cancer development in older women. Exogenous
estrogen commonly comes in the form of oral contraceptives and hormone replacement
therapy (HRT). Research suggests that oral contraceptives are more strongly associated
with ER-negative tumors than ER-positive tumors, though the side effects of oral
contraceptives has been greatly reduced since their original production. Women who stop
using oral contraceptives for more than 10 years can completely eliminate their risk of
developing breast cancer from exogenous estrogen. Additionally, studies have shown that
the use of HRT can increase the risk of developing breast cancer. The Million Women
Study in UK showed that women who currently take HRT have a relative risk (RR) of
1.66 for developing breast cancer when compared to those who have never used HRT
(24). In 2003, the Women’s Health Initiative published data reflecting the negative
effects of HRT. Since then, the incidence rate of breast cancer caused by HRT has
dropped 7% (24).
Unhealthy eating and drinking habits can also increase one’s risk of developing
breast cancer. It is recognized that early-life exposure to carcinogens can increase a
women’s lifetime risk of breast cancer. Breast cancer risk builds over the course of a
lifetime, but research suggests that the majority of the buildup occurs between menarche
and first pregnancy. There appears to be a critical period after the onset of menarche,
when breast tissue is growing and dividing rapidly, all the way until the first pregnancy.
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Thus alcohol, which is a breast carcinogen, if consumed early in life, could contribute to
increased breast cancer risk. Specifically, daily excessive alcohol consumption can
increase the risk of breast cancer by 32% (24). Case-control studies showed that alcohol
consumption (1 drink/day) before the age of 30 increased the risk of premenopausal
breast cancer by 34% (13). However, in the same study it was shown that alcohol
consumption before the age of 30 did not affect postmenopausal women. This is further
evidence that a critical period could exist in breast cancer development. Eating a healthy
diet alone is not enough to prevent breast cancer, but it can contribute to lowering one’s
risk for developing it. Several vitamins and natural phenols have been identified as
potential substances that can help to fight and or treat breast cancer. Resveratrol, a natural
phenol, will be discussed later in this paper.
The development of breast cancer does not happen in one step, it is a multifaceted
disease that takes time to develop. Some stages are much less dangerous than others, so
doctors need a way to describe which stage a tumor is in at a certain time. In order to do
this, doctors use a tumor, node, and metastasis (TNM) staging system (4). The following
stages have been created to show tumor progression: normal epithelial cells, hyperplasia,
hyperplasia with atypia, and carcinoma in situ invasive cancer. Typically, breast cancer
begins in the milk-producing ducts of the breast. Often considered stage 0, ductal
carcinoma in situ is a type of non-invasive breast cancer. It is characterized by the
development of abnormal epithelial cells lining the milk ducts of the breast. While this
stage is not considered life-threatening, treatment is still recommended to prevent further
growth and spreading. In stage 1 breast cancer, the tumor is less than two cm in size, but
the cancer is now considered invasive. The tumor has not spread to other parts of the

14

body at this point and successful treatment is still very likely. Even though stage 1 is not
considered life threatening, treatment usually immediately follows a diagnosis. Stage 1
breast cancer is highly treatable, with radiation and/or surgery being the two most
common treatment plans (20). In addition to radiation and surgery, a person with stage 1
breast cancer could also consider hormone therapy. Hormone therapy for breast cancer
can be very effective if the particular type of breast cancer is sensitive to hormones. It
works by blocking a hormone from attaching to its receptor or by blocking hormone
production, thus blocking the function of the hormone (11). Stage 2 breast cancer is
characterized by increased tumor growth, but the tumor is still contained in the breasts or
nearby lymph nodes. Stage 2 is further divided in two groups: A and B. Stage 2A breast
cancer can be applied to three different scenarios. The first scenario includes no tumor
present but cancer cells have spread to the lymph nodes. The second scenario is that the
tumor is less than two cm in size and has spread to the lymph nodes. Finally, the tumor
has to be two to five cm in size and have not spread to the lymph nodes to be included in
stage 2A. Stage 2B breast cancer is defined by 2 different situations. If the tumor is 2-5
cm in size and has spread to less than four nearby lymph nodes, then it is in stage 2B.
Additionally, if the tumor grows to be larger than five cm, but has not spread to any
lymph nodes, then it is in stage 2B (22)
Stage 3 breast cancer means the cancer has spread beyond the primary tumor site
and may have invaded nearby tissues, but has not spread to distant organs. Stage 3 breast
cancer is divided in to 3 groups: 3A, 3B, and 3C. The difference between stages is
determined by the size of the tumor and whether the cancer has spread to the lymph
nodes and surrounding tissue. Although stage 3 breast cancer is considered advanced,
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there is a growing number of treatment options available. Stage 3 treatment options
include mastectomy, radiation, hormone therapy, and chemotherapy. A combination of 2
or more treatments is typically the most effective for this stage (21). Stage 4 breast cancer
means that the cancer has spread to other parts of the body, such as the brain, bones,
lungs, and liver. Stage 4 breast cancer is considered incurable, but new treatments have
prolonged the lives of stage 4 breast cancer patients (19). During this stage of cancer,
patients can be exposed to experimental treatments if they are willing.

Tumor Formation:
Reactive oxygen species (ROS) consist of radical and non-radical oxygen species
that have partially reduced oxygen molecules. These ROS are important regulators of
homeostasis in moderate concentrations, but can become a major health problem if
present in high concentration (7). Much of cellular ROS production is a by-product of
oxidative phosphorylation occurring in the mitochondria but ROS can also be produced
during an immune response to foreign substances. Oxidative stress can occur when there
is an imbalance between the concentration of ROS and an antioxidant response.
Oxidative stress caused by ROS has been shown to damage nucleic acids, proteins, and
lipids (7). Additionally, ROS have the ability to promote disease formation (such as
cancer) through signaling pathways. For example, ROS have been shown to promote cell
proliferation, survival, and differentiation by activating the PI3K pathway. However,
ROS have also been shown to induce apoptosis and cellular aging in certain cell lines.
Therefore, how a cell reacts to ROS depends on its molecular background and
surrounding environment. At high concentration, ROS can cause apoptosis in cancer cells
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due to cellular damage. However, ROS plays a much larger role in signal transduction in
tumor formation, progression, and survival.
Many cancers form solid masses of tissue called tumors after a period of time.
The word tumor has a Latin origin that translates to “swelling” in English but not all
swellings can be considered tumors. Wallace H. Clark, a celebrated pathologist, defined
tumors as meeting the following criteria; they consist of cells experiencing temporally
unrestricted growth, and the ability to grow in at least three different tissue
compartments. Included in these compartments are the original site, the mesenchyme of
the primary site, and the mesenchyme of a distant site. This definition of a tumor
encompasses the benign beginning, invasive nature, and potential to spread that tumors
have. Tumors consist of two separate but interdependent compartments. The parenchyma
consists of neoplastic cells that exhibit uncontrolled growth. The other compartment, the
stroma, consists of the connective tissue, blood vessels, and other components that keep
the tumor alive and allow it to grow. All tumors that grow beyond one to two mm in size
require stroma for survival. Tumor stroma is formed from circulating components of the
blood. These elements are able to enter tissues in areas that consist of high levels of
vascular endothelial growth factor (VEGF-A), which promotes high vascular
permeability. The angiogenic growth factor, VEGF-A, is the most studied and well
known in a family of proteins that also consists of vascular endothelial growth factors B,
C, D, and E. Additionally, VEGF-A acts as a cytokine that serves many functions and is
produced by both animals and humans. Among its many other activities, VEGF-A plays a
large part in the immune response. Its vascular permeability inducing activity facilitates
elements from the blood to enter wound sites and aid in the healing process. However,
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VEGF-A plays a monumental role in the development of cancer. In addition to its role in
stroma formation, VEGF-A contributes greatly to angiogenesis (the formation of new
blood vessels) by binding to and activating vascular endothelial growth factor receptors
(VEGFR). Upon VEGF binding to VEGFR, a tyrosine kinase cascade is activated,
signaling new blood vessels to form. These new blood vessels are not the same as
healthy, normal blood vessels. They are often leaky, disorganized, and have irregular
blood flow. Further, VEGF-A plays a critical role in embryonic development and woundhealing in adults. However, VEGF-A is overexpressed in cancerous cells causing a large
increase in angiogenesis, which is a hallmark of cancer.
The heterodimeric transcription factor hypoxia-inducible factor-1 (HIF-1), is the
primary activator of VEGF-A (17). Under normoxic conditions, its hypoxia-regulated
HIF-1α subunit is proteolytically degraded very quickly, with a physiological half-life of
about five minutes. In the presence of oxygen, divalent iron ions bind to the proline or
asparagine residues of HIF-1α and promote is rapid proteolysis. However, HIF-1α is
stable and present in high levels in hypoxic environments, where it heterodimerizes with
the constitutively expressed HIF-1β subunit, and activates the herterodimeric
transcription factor complex known as HIF-1. Because of the irregularities of tumor
vasculature, the tumor microenvironment is typically hypoxic, which leads to an increase
in oncogene expression of HIF-1α. When activated by HIF-1, VEGF-A promotes tumor
angiogenesis. Tumors are able to grow in size with the development of new blood vessels
that feed the tumor. Thus, tumors are able to take advantage of the hypoxic environment
that their vasculature creates in order to grow and survive.
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The transcription factor HIF-1 also has a prominent role in the regulation of
oxidative phosphorylation and ROS production. When ROS are present in high levels,
HIF-1 can suppress ROS formation by inhibiting the mitochondrial tricarboxylic acid
cycle. Low concentrations of ROS can trigger HIF-1 to increase ROS formation through
NADPH oxidase (7). In healthy cells, ROS formation is a byproduct of oxidative
phosphorylation and is present in minimal concentrations due to antioxidant systems.
When these systems fail and ROS concentrations rise, oxidative damage can follow.
Additionally, ROS have been shown to stabilize HIF-1α, which leads to HIF-1α
accumulation and subsequent HIF-1 activation. Therefore, it is possible that ROS play a
major role in tumor angiogenesis by stabilizing HIF-1α.

Metastasis:
One of the major issues with cancer is its ability to spread to other parts of the
body. In a process called metastasis, cancer can spread locally into nearby tissues or to
distant parts of the body through the circulatory or lymphatic systems. Nearly all types of
cancer have the potential to become metastatic (6). Individual and environmental factors
determine whether or not the cancer will become metastatic. There are three common
ways metastasis can occur: by growing directly into tissue surrounding the tumor,
traveling through the bloodstream, or by traveling through the lymphatic system.
Metastasis is composed of several steps that leads to the spread of cancer throughout the
body in a process known as the metastatic cascade. Metastasis begins when cancer cells
detach from the primary tumor site in a process called invasion (25). The route of the
detached cancer cell depends on the location of the primary tumor. For example, a breast
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cancer tumor undergoing metastasis has the potential to invade the lungs, brain, lymph
nodes, or liver. Many factors can contribute to cell detachment, including tumor growth,
necrosis, and enzyme activity. Cancer cells can undergo an epithelial-mesenchymal
transition (EMT) to gain migratory abilities. The process of EMT can be initiated by
signaling from growth factors such as TGF-b or from cell proliferation proteins such as
Wnt (25). Initiating EMT increases the expression of EMT transcription factors that are
involved with the downregulation of epithelial cadherins (proteins that promote cell-cell
binding). Many studies have shown that ROS are major activators of EMT by acting as
secondary messengers. The growth factor, TGF-b, regulates urokinase type plasminogen
activator (uPA) and matrix metallopeptidase 9 (MMP-9) through an ROS mechanism
(12). This results in a weaker bond between cancer cells and the tumor, promoting
detachment and leading to an increase in cell-stroma interactions (25). After a cancer cell
detaches from the primary tumor, it begins a perilous journey around the body.
Intravasation is the process by which cancer cells enter the circulatory system
through blood or lymphatic vessels. These circulating tumor cells (CTCs) are often killed
by stress or the immune system, or they can become lodged in a capillary bed where they
form a new tumor. This circulation process is very inefficient, with only 0.01% of CTCs
actually forming a distant tumor (8). However, it is very important to study and
understand intravasation because it is a major part of the deadly metastatic cascade. The
content of the tumor microenvironment, proteases, and signaling molecules all play a part
in the process of intravasation. Angiogenesis is the process by which new blood vessels
form, so it follows that tumors with a higher degree of angiogenesis could also
experience higher levels of intravasation. As mentioned earlier, VEGF-A plays a large
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part in increasing vascular permeability and blood vessel formation. Additionally, VEGFA leads to an increase in microvessel density, which has been linked to an increase in
intravasation (8). The primary activator of VEGF-A, HIF-1, is also an activator of
proteases known as matrix metalloproteinases (MMPs). These zinc-dependent
endopeptidases are responsible for the breakdown of the extracellular matrix (ECM),
which serves as the physical barrier between tumor cells and blood and lymphatic
vessels. Once cancer cells are able to enter into the circulatory system, they have the
potential to invade other parts of the body. If these cells are able to establish themselves
in other tissues, the result is often lethal.
Extravasation is the process by which CTCs exit the circulatory system to form
secondary tumors. Once CTCs are in their new location, they go through a mesenchymalepithelial transition (MET) to form a new tumor. Extravasation is a very dynamic process
and is not as well understood as the previous steps of the metastatic cascade. However,
further research should be conducted on this process because of its potential as a target
for anti-metastatic drugs.

Treatment:
Breast cancer is the deadliest form of cancer among women in the world (18). It is
more prevalent in developed countries, but the mortality rates are much higher in poorer
countries because of fewer and inferior treatment options. The high incidence of breast
cancer has made it become one of the most widely studied forms of cancer. Early
detection in the form of biomarkers has served as a huge step towards curing breast
cancer. Estrogen (ER) and progesterone (PR) receptors have been the most widely
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studied biomarkers for early breast cancer detection and prevention. Additionally,
advances in DNA technology have allowed researchers to target early breast cancer
detection at the level of DNA processing. However, thousands of people still die from
breast cancer every year and countless more suffer from a lower quality of life from the
side effects of the toxic drugs that they have to take to survive. The most common form
of treatment for metastatic breast cancer is surgery, but almost all treatment plans use a
combination of therapies. Radiotherapy, chemotherapy, and immune therapy are also
common treatment options. Resistance to therapies and high toxicity of primary treatment
options have led researchers to look in to more natural options for breast cancer
treatment. Phytochemicals, a large family of bioactive compounds found in plants, have
emerged as leading candidates for the management and prevention of breast cancer (18).
Several phytochemicals have been shown to induce apoptosis in breast cancer cells and
prevent the growth of tumors by inhibiting angiogenesis, causing DNA damage through
oxidative stress, controlling proliferation, and overtaking cell signaling pathways. In this
review, breast cancer cell lines were treated with resveratrol, a non-flavonoid polyphenol.
Resveratrol (trans-3,4′,5-trihydroxystilbene, C14H12O3) is a naturally occurring
polyphenol that is present in grapes, berries, peanuts, soy beans, and certain fungi (18).
Resveratrol is thought to have beneficial effects on the human heart. The French consume
a high amount of red wine, which is rich in saturated fat, yet they have few heart related
problems. This “French Paradox” is thought to be related to the beneficial effects of
resveratrol. Additionally, resveratrol has been shown to have various benefits in
coronary, neurological, hepatic, and cardiovascular systems (18). It has been shown to
fight inflammation, reduce reactive oxygen species, freeze the cell cycle, restore
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apoptosis, and slow cancer cell growth in various cell lines. Mitochondrial Complex I
releases superoxide radicals into the mitochondrial matrix, where mitochondrial
manganese SOD (SOD2) converts the superoxide radicals to hydrogen peroxide. Next,
hydrogen peroxide is converted to water by glutathione peroxidases (GSH). Resveratrol
has been shown to be a scavenger of certain oxidants including superoxide radicals and
hydrogen peroxide. However, resveratrol is only effective at scavenging low levels of
ROS. Instead, resveratrol’s best antioxidant properties work at the level of DNA
transcription (28).

Figure 1. Resveratrol Structure. This image was created using ChemDoodle3D.

Interestingly, resveratrol has been shown to have prooxidative and antioxidative
properties. Resveratrol is well-known as an antioxidant, but it can act as a prooxidant in
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the presence of certain transition metals such as copper (18). As described earlier, ROS
are able to damage macromolecules such as DNA when present in high concentrations. If
ROS could be contained to a tumor site, then ROS generation could potentially be an
avenue for cancer treatment by damaging DNA and preventing cell growth and
proliferation. On the other hand, resveratrol is known to be a scavenger of ROS. It is able
to stabilize free radicals by forming a resonance-stabilized peroxyl radical, thus
diminishing the effects of ROS. In this way, resveratrol is preventing the accumulation of
ROS, which can lead to cancer by damaging healthy DNA. Resveratrol is also involved
with an increase in antioxidant enzymes, such as superoxide dismutase (SOD). The
antioxidant properties of resveratrol have also been shown to have a synergistic effect
when combined with certain chemotherapeutic agents. Many chemotherapeutic drugs
work through a pro-oxidant mechanism, leading to a buildup of ROS that can cause
toxicity in the body. In one study, Resveratrol protected against cardiotoxicity in H9c2
cardiomyocytes that were treated with doxorubicin by blocking ROS production through
the upregulation of manganese superoxide dismutase (18). This review focuses on the
antioxidant properties of resveratrol.
Cancer stem cells (CSCs) are cancer cells that have similar properties to normal
stem cells, specifically the ability to become any cell type found in the body. Cancer stem
cell theory has gained much traction over recent years. This theory suggests that there is a
small subpopulation of cells within the tumor that are responsible for the persistence of
the disease. Other cells can still cause problems, but the CSCs are the root of the issue
according to this theory (23). Cancer stem cell theory suggests that if the CSCs are not
destroyed but the signs of cancer have been eliminated, then the cancer will grow back.
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Most chemotherapies and radiotherapies do not target CSCs. Thus, many new anticancer
drugs are now focusing on this small subpopulation of cells to combat tumor growth.
These drugs could work by re-sensitizing CSCs to chemotherapy drugs or blocking selfrenewal pathways. In a number of studies, resveratrol has been shown to slow or halt the
differentiation of the CSCs directly and indirectly (18).
Adjuvant therapy is treatment that is given in addition to the primary treatment
(surgery, chemotherapy, etc.) Phytochemicals, such as resveratrol, have proven to be one
of the most effective adjuvant treatment drugs. These compounds are able to reverse drug
resistance in some tumors and increase sensitivity to drugs in others. Resveratrol has been
shown to increase the antitumor activities of drugs such as doxorubicin, which belongs to
the class of chemotherapy drugs known as anthracyclines. Anthracyclines inhibit
topoisomerase 2, which cells need to divide and grow. Resveratrol, when combined with
doxorubicin, has been able to increase the power of doxorubicin without affecting normal
cells. Carbonyl reductase 1 (CBR1) catalyzes the reaction of doxorubicin to
doxorubicinol, which causes cardiotoxicity and diminishes the antitumor potential of
doxorubicin. If CBR1 is present in high levels, chemoresistance of tumor cells is
enhanced. Resveratrol has the ability to bind to CBR1, thus re-sensitizing cancer cells to
doxorubicin. A case control study performed from 1993-2003 examined the effect of
resveratrol intake in breast cancer patients. There were 369 patients that were given
resveratrol, and 602 patients that were not. The study showed that breast cancer risk was
decreased in the patients taking resveratrol (18).
In the experiments performed by the research group, we studied the effects of
resveratrol, vitamins C and E, and epigallocatechin gallate (EGCG) on several breast
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cancer cell lines. This review will focus on the antioxidant therapeutic capabilities of
resveratrol.

Natural Product Studies:
The research team began working in the spring of 2019 and conducted research
under the direction of Dr. Zhou and Dr. Nagle until spring 2020. We began with literature
research into breast cancer to gain a better understanding of the mechanisms underlying
this complicated disease. After deciding to pursue research regarding the effects of
certain compounds on breast cancer cell lines, Dr. Zhou advised us to find a less studied
compound to increase the originality. While it is difficult to be completely original in this
field, background research increased our knowledge of the field and helped us select a
topic. Literature review showed us that resveratrol has been studied in various ways over
the past decade. For example, resveratrol has been shown to have positive effects on the
heart, kidneys, and cancer patients (18). After selecting a compound to study, a plan was
created to study the effects of resveratrol, vitamins C and E, and EGCG on various breast
cancer cell lines. The chemotherapeutic experiment consisted of literature research, cell
culture procedures, and a viability assay. Experiments were concluded in November 2019
and the data analysis and writing process began soon after. Our general hypothesis stated
that these compounds (resveratrol, vitamins C and E, EGCG) would cause damage to
certain breast cancer cell lines or inhibit their growth.
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Materials and Methods:

Sulforhodamine B (SRB) Viability Assay:
The Sulforhodamine B (SRB) assay is a widely used method to determine
cytotoxicity in cell-based studies in a relatively inexpensive and efficient manner (16).
Sulforhodamine B is a fluorescent dye that binds to proteins under acidic conditions and
can be used to determine cell inhibition/apoptosis. This assay was used after the cells
were seeded in a 96-well plate with a cell density of 30,000 cells/well and 100 mL/well
of media. First, cells were trypsonized with 1.0 mL Trypsin. This step was performed to
prevent cell-cell attachment. Next, the cells were washed with 10 mL of 10% fetal bovine
serum (FBS) media. Then, the plates were cultured at 37° C for 24 hours. After 24 hours,
test compounds diluted in serum-free RPMI 1640 media with L-glutamine (2 mM),
penicillin, and streptomycin were added (100 mL/well.) The compounds were prepared
as stock solutions in DMSO with a final concentration of 0.25% (v/v). After 48 hours,
100 µL of media was removed from each well. 100 µL of 20 % trichloroacetic acid
(TCA) in 1x PBS solution were then added to each well to begin the staining process.
The wells were then incubated at 4° C for 1 hour. Next, the wells were washed with tap
water and then stained with 100 µL of 0.4% SRB (w/v, 1% acetic acid). The plates were
then washed 4 times with 1% acetic acid and allowed to dry. Then, Tris Base (100 µL of
10 mM) was added to each well at a volume of 200 mL/well. The wells were shaken for
10 minutes and were then ready to be analyzed using the SpectaFluor plate and Magellan
software. The absorbance range was set to 496-620 nm. The Magellan software was able
to calculate the inhibition value by analyzing the total protein mass density in each well.
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Cell viability data is presented as percent control using the formula: % Control =
(ODcompound/ODcontrol) x 100.

MCF-7
1

BOM
2

3

4

5

6

MD-MBA-231

MCF-7-BOM

7

10

8

9

A

Media Control 100 µL (negative control)

B

Media Control 100 µL (negative control)

C

1 µM Resveratrol

D

10 µM Resveratrol

E

30 µM Resveratrol

F

100 µM Resveratrol

G

300 µM Resveratrol

H

10 µM Cycloheximide (positive control)

11

Figure 2. Resveratrol Concentrations in 96-Well Plate Layout

Natural Product Dilution Plate
The chemotherapeutic agents were purchased from Sigma Aldrich or The
Association of Clinical Research Organizations (ACRO). For this experiment, we set the
stock solution concentration at a range from 1 µM to 300 µM for each compound. DMSO
was added to each chemotherapeutic agent to acquire the desired stock concentration for
the experiment. Fetal bovine serum (FBS) was used as media to dilute the stock solutions
to the highest tested concentration. A 1:10 serial dilution was performed in a stepwise
manner as can be seen in the table below.
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Resveratrol solution
300 µM
100 µM
30 µM
10 µM
1 µM

Stock Dilution
50.4 µL of 50 µM
1.1 mL of 300 µM
330 µL of 300 µM
330 µL of 100 µM
300 µL of 10 µM

Media Volume
4.15 mL
2.2 mL
2.97 mL
2970 mL
2700 mL

Figure 3. Serial Dilution of Resveratrol

Cell Lines:
Four cancer cell lines were used in this experiment: MCF-7, BOM 231, MDAMB-231, and MCF-7-BOM. The MCF-7 is a human breast cancer cell line with estrogen,
progesterone, and glucocorticoid receptors (5). It was derived from a 69-year old
Caucasian woman with adenocarcinoma in 1970 by Dr. Herbert Soule. MCF-7 is very
useful for in vitro studies because of its ability to process estrogen as an in vivo breast
cancer cell would. The MDA-MB-231 cell line is a triple-negative breast cancer cell line
that was derived from a 51-year-old Caucasian female with invasive ductal carcinoma in
1970 (26). This cell line is highly aggressive, invasive and lacks estrogen and
progesterone receptors, and does not overexpress HER2. Additionally, this cell line has a
mutated p53 (tumor suppressor) gene. MDA-MB-231 cells are invasive when implanted
and metastasize to lymph nodes in vivo. This cell line also commonly metastasizes to the
lung and bone to form secondary tumors. The BOM 231 is a cell line from metastatic
bone cancer that was derived from the secondary tumors of MDA-MB-231. The BOM
231 cell line was generated in Dr. J. Massagúe’s lab at Memorial Sloan Kettering Cancer
Center, New York City, New York. The specific BOM 231 cell line that we used was
acquired from Dr. Konosuke Watabe at Wake Forest University. The MCF-7 BOM is
also a metastatic bone cancer cell line that was derived from secondary tumors formed by
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the breast cancer cell line MCF-7. The MCF-7-BOM was also generated in Dr. J.
Massagúe’s lab at Memorial Sloan Kettering Cancer Center, New York City, New York.
We acquired MCF-7-BOM cells from Dr. Konosuke Watabe at Wake Forest University.
All cell lines were maintained in RPMI 1640 media with L-glutamine (2 mM)
(Mediatech), supplemented with fetal bovine serum [FBS, 10% (v/v), Hyclone],
penicillin (50 units/mL), and streptomycin (50 µg/mL) (Lonza) in an atmosphere
containing 5% CO2 and 95% air at 37° C.
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Results:
Figure 4 was created to compare results under normoxic and hypoxic conditions,
as well as treatment with cycloheximide, which was the positive control in this
experiment. In all cell lines except for MCF-7-BOM, cell viability and proliferation from
the media control was reduced under hypoxic conditions compared to normoxic
conditions. Hypoxic conditions result when there is an absence of oxygen in the
physiological system, which can lead to stress on a cell because they have to switch to
anaerobic respiration to produce energy. Anaerobic respiration is not as efficient as
aerobic respiration, which could lead to cell stress and eventually apoptosis. The graphs
from Figure 4 were created relative to the normoxic control, which was set at 100% cell
survival.

BOM 231

1.5

Normoxia
Hypoxia

1.0

0.5

0.0
Media Con.

Relative of Normoxic Con.

Relative of Normoxic Con.

MCF7
1.5

Normoxia
Hypoxia

1.0

0.5

0.0
Media Con. CHX (10 uM)

CHX (10 uM)
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7-BOM

1.5

Normoxia
Hypoxia

1.0

0.5

0.0

Relative of Normoxic Con.

Relative of Normoxic Con.

MDA MB 231
1.5

Normoxia
Hypoxia

1.0

0.5

0.0
Media Con. CHX (10 uM)

Media Con. CHX (10 uM)

Figure 4. Normoxia, hypoxia, and cycloheximide (CHX) compared to normoxic media
control.

SRB Viability Assay
The results of the Sulforhodamine B viability assay reflect the percent inhibition
values of resveratrol tested on the cell lines MCF-7, BOM-231, MDA-MB-231, and
MCF-7-BOM. The goal of this assay was to acquire an IC50 value, which is the drug
concentration where cell growth is inhibited by 50%. This means that a lower IC50 value
indicates a more effective drug. However, while each cell line and condition showed
inhibition, only MCF-7 normoxia and hypoxia, and BOM 231 hypoxia were inhibited
enough for an IC50 value to be calculated within the highest concentration of resveratrol
tested. Prism Graphpad 8 was able to calculate an IC50 value for all cell lines, but only
three of the cell lines fell within the range of concentrations tested. The other cell lines
had an IC50 value over 300 µM. The following charts reflect percent inhibition of
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resveratrol on each cell line that were incubated under either of two conditions: normoxia
or hypoxia. These graphs were created using Prism GraphPad 8.
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Figure 5. Percent Tumor Cell Inhibition Data
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Discussion
From the SRB assay, resveratrol was shown to be capable of inhibiting cell
proliferation in a concentration and cell line dependent manner. The MCF-7 cell line
proved to be the most susceptible to resveratrol treatment in both normoxic and hypoxic
conditions at maximum resveratrol concentration. This cell line also showed an increase
in % inhibition when the concentration of resveratrol was increased in both conditions.
The MCF-7 cell line could be the most susceptible because it is an ER+ cell line and
resveratrol has shown to have phytoestrogen properties. The resveratrol IC50 value was
the smallest in the MCF-7 normoxia cell line, indicating that this cell line was the most
susceptible to resveratrol treatment. Resveratrol was also effective at inhibiting the MCF7 hypoxia cell line, which produced the second smallest IC50 value. The BOM 231
hypoxia was the only other cell line that produced an IC50 value that was lower than the
maximum resveratrol concentration tested. All IC50 values were calculated and fall into a
95% confidence interval (CI) as shown in Figure 6. These values were calculated using
prism GraphPad 8. The cell lines that produced IC50 values less than the maximum
concentration of resveratrol (300 µM) tested are highlighted in green, while those that
had an IC50 value greater than 300 µM are highlighted in red.

Cell line

IC50 (M)

95% CI (M)

MCF-7 Normoxia

0.0001364

0.000095995 to 0.001

MCF-7 Hypoxia

0.0001467

.00009323 to 0.001

BOM 231 Normoxia

0.0003572

0.0002736 to 0.001304

BOM 231 Hypoxia

0.0002563

0.0001634 to 0.0005
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MDA-MB-231 Normoxia

0.0003442

0.0001206 to 0.0009

MDA-MB-231 Hypoxia

0.0004277

0.0002177 to 0.001

MCF-7 BOM Normoxia

0.001024

0.00009873 to 2.652

MCF-7 BOM Hypoxia

0.01951

0.0001263 to 3.12

Figure 6. IC50 Values for all Cell Lines

This study was successful in showing that resveratrol is capable of slowing and/or
inhibiting cell growth in certain breast cancer cell lines. However, the exact mechanism
of how this occurs is an area that requires further study. One potential area of study could
be examing resveratrol antioxidant effects in certain cancer cell processes. For example,
as mentioned earlier, the PI3K pathway relies on ROS to promote cellular proliferation.
Resveratrol is a known scavenger of ROS and could potentially inhibit this pathway.
Additonally, the role of resveratrol as a pro-oxidant in breast cancer treatment could be
an interesting avenue for further research. A major hurdle to this research would be to
find a way to limit ROS generation to the tumor site, which could lead to cancer cell
apoptosis.
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Conclusions
In conclusion, resveratrol was tested on several different cancer cell lines to
determine its efficacy as a chemotherapeutic compound. Resveratrol proved to be capable
of inhibiting cell growth and proliferation in cell lines and the results were much more
profound in specific cell lines. While this study produced results that could lead to
resveratrol gaining a bigger role as a chemotherapeutic compound, much more research
needs to be conducted to understand the exact mechanism by which this compound
works. Additionally, these experiments should be repeated in order to ensure that the data
provided from this report is accurate. The hypothesis that resveratrol would show cell
line-dependent inhibition is supported by the percent inhibition data produced from the
SRB viability assay. The MCF-7 cell line was the most sensitive to resveratrol, possibly
because of the presence of estrogen receptors in that cell line. However, more
experiments should be conducted using higher concentrations of resveratrol to acquire
precise IC50 values for all cell lines.

37

References
1.

BRCA: The breast cancer gene. (n.d.). Retrieved January 21, 2020, from National
Breast Cancer Foundation, Inc website:
https://www.nationalbreastcancer.org/what-is-brca

2.

Breast cancer anatomy and how cancer starts. (n.d.). Retrieved January 25, 2020,
from National Breast Cancer Foundation website: https://nbcf.org.au/about-breastcancer/diagnosis/breast-cancer-anatomy/

3.

Breast cancers facts and figures 2017-2018. (n.d.). Retrieved from:
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-andstatistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-20172018.pdf

4.

Breast cancer: Stages. (n.d.). Retrieved January 21, 2020, from Cancer.net
website: https://www.cancer.net/cancer-types/breast-cancer/stages

5.

Camarillo, I. G., Xiao, F., Madhivanan, S., Salameh, T., Nichols, M., Reece, L.
M., & Sundararajan, R. (2014). 4 - Low and high voltage electrochemotherapy for
breast cancer: an in vitro model study. In Electroporation-Based Therapies for
Cancer (pp. 55-102). Retrieved from
https://www.sciencedirect.com/science/article/pii/B9781907568152500042

6.

Cancer. (2018, September 12). Retrieved January 25, 2020, from World Health
Organization website: https://www.who.int/news-room/fact-sheets/detail/cancer

7.

Chen, R., Lai, U. H., Zhu, L., Singh, A., Ahmed, M., & Forsyth, N. R. (n.d.).
Reactive oxygen species formation in the brain at different oxygen oevels: The

38

Role of Hypoxia Inducible Factors. Frontiers in Cell and Developmental Biology.
Retrieved from https://www.frontiersin.org/articles/10.3389/fcell.2018.00132/full
8.

Chiang, S. P.H., Cabrera, R. M., & Segall, J. E. (2016). Tumor cell intravasation.
American Journal of Physiology, 311(1). Retrieved from
https://journals.physiology.org/doi/full/10.1152/ajpcell.00238.2015

9.

Genetics. (n.d.). Retrieved January 21, 2020, from Breastcancer.org website:
https://www.breastcancer.org/risk/factors/genetics

10. Holland, J. F., Frei, E., & Kufe, D. W. (2003). Tumor structure and tumor stroma

generation. In Cancer medicine (6th ed.). Retrieved from PMC database.
11. Hormone therapy for breast cancer. (2019, February 5). Retrieved January 25,

2020, from Mayo Clinic website: https://www.mayoclinic.org/testsprocedures/hormone-therapy-for-breast-cancer/about/pac-20384943
12. Liao, Z., Chua, D., & Tan, N. S. (2019). Reactive oxygen species: a volatile driver

of field cancerization and metastasis. Molecular Cancer, 18(65).
https://doi.org/10.1186/s12943-019-0961-y
13. Liu, Y., Nguyen, N., & Colditz, G. A. (2015). Links between alcohol consumption

and breast cancer: a look at the evidence. Women's Health (London, Eng), 11(1),
65-77. https://doi.org/10.2217/whe.14.62
14. Melzer, C., von der Ohe, J., & Hass, R. (n.d.). Breast carcinoma: from initial

tumor cell detachment to settlement at secondary sites. NCBI, pp. 1-2.
https://doi.org/10.1155/2017/8534371

39

15. Ocana, A., Amir, E., & Pandiella, A. (2020). HER2 heterogeneity and resistance

to anti-HER2 antibody-drug conjugates. Breast Cancer Research, 22(15).
Retrieved from Springer Nature database.
16. Orellana, E. A., & Kasinski, A. L. (1984). Sulforhodamine B (SRB) assay in cell

culture to investigate cell proliferation. Bio Protocol, 6(21).
https://doi.org/10.21769/BioProtoc.1984
17. Ramakrishnan, S., Anand, V., & Sabita Roy. (n.d.). Vascular endothelial growth

factor signaling in hypoxia and inflammation. NCBI.
https://doi.org/10.1007/s11481-014-9531-7.
18. Sinha, D., Sarkar, N., Biswas, J., & Bishayee, A. (2016). Resveratrol for breast

cancer prevention and therapy: Preclinical evidence and molecular mechanisms.
Elsevier, 40(41), 209-232.
19. Stage 4 (IV). (n.d.). Retrieved January 21, 2020, from National Breast Cancer

Foundation, Inc website: https://www.nationalbreastcancer.org/breast-cancerstage-4
20. Stages 0 & 1. (n.d.). Retrieved January 21, 2020, from National Breast Cancer

Foundation, Inc website: https://www.nationalbreastcancer.org/breast-cancerstage-0-and-stage-1
21. Stage 3 (III) A, B and C. (n.d.). Retrieved January 21, 2020, from National Breast

Cancer Foundation, Inc website: https://www.nationalbreastcancer.org/breastcancer-stage-3

40

22. Stage 2 (II) and stage 2A (IIA). (n.d.). Retrieved January 21, 2020, from National

Breast Cancer Foundation, Inc website:
https://www.nationalbreastcancer.org/breast-cancer-stage-2
23. The stem cell theory of cancer. (n.d.). Retrieved February 1, 2020, from Stanford

Medicine website: https://med.stanford.edu/ludwigcenter/overview/theory.html
24. Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., . . . Zhu, H.-P.

(2017). Risk factors and prevention of cancer. NCBI, 13(11).
https://doi.org/10.7150/ijbs.21635
25. Wang, Z., Li, Y., & Sarkar, F. H. (2010). Signaling mechanism(s) of reactive

oxygen species in epithelial-mesenchymal transition reminiscent of cancer stem
cells in tumor progression. Current Stem Cell Research and Therapy, 5(1), 74-80.
Retrieved from NIH database.
26. Welsh, J. (2013). Animal models for studying prevention and treatment of breast

cancer. In Animal Models for the Study of Human Disease (pp. 997-1018).
Retrieved from
https://www.sciencedirect.com/science/article/pii/B9780124158948000403
27. What is breast cancer. (n.d.). Retrieved December 1, 2019, from American Cancer

Society website: https://www.cancer.org/cancer/breast-cancer/about/what-isbreast-cancer.html
28. Xia, N., Daiber, A., Fostermann, U., & Li, H. (2017). Antioxidant effects of

resveratrol in the cardiovascular system. British Journal of Pharmacology,
174(12), 1633-1646. https://doi.org/10.1111/bph.13492

41

29. Zhou, M., Hou, J., Li, Y., Mou, S., Wang, Z., Horch, R. E., & Yuan, Q. (2019).

The pro-angiogenic role of hypoxia-inducible factor stabilizer FG-4592 and its
application in an in vivo tissue engineering chamber model. Scientific Reports,
9(6035). Retrieved from nature database.

42

